IM

Insilico Medicine

Organization

Heard in 13 episodes across 5 shows since Aug 2026

A biotechnology company using artificial intelligence for drug discovery, target identification, molecular design, and aging-related research.

Episodes

13
across 5 shows

First heard

Aug 2026

Expert statements

5
4 positive · 1 negative

Episodes per month

Public PodLume episodes featuring it, over the last year.

Show the data
MonthEpisodes
Dec 20250
Jan 20260
Feb 20260
Mar 20260
Apr 20260
May 20260
Jun 20260
Jul 20260
Aug 20261
Sep 20268
Oct 20261
Nov 20263

Email alert

Email me when Insilico Medicine comes up on a podcast

One email a week at most, with the new episodes that mention Insilico Medicine. Free, no account needed, unsubscribe in one click.

What experts have said about Insilico Medicine

5 statements · 4 positive · 1 negative

  1. Insilica lacks a proven business model and sustainable consistent profitability.

    “it's a fairly recent float. We've described it as not really having a proven business model as yet.”

    Listen at 6:31

    Open the episode · Morning Movers!
  2. Anthony StevensPositiveSep 30, 2026· Stock Movers

    Insilico shares rose about 8% after releasing an obesity-targeting molecule.

    “Insilico, which is an AI-driven drugs developer, that's up around 8% as it releases a molecule to perhaps tackle obesity”

    Listen at 1:11

    Open the episode · Insilico Rises, Hygon Dips, AOU Gains
  3. “So that I think is quite positive actually, because we've been flagging for a while that the balance sheet's too thin and it does need more cash.”

    Listen at 21:12

    Open the episode · Paul's Podcast - Fri 13 Mar 2026

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

13 episodes featuring Insilico Medicine, newest first